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Abstract
Objective Adjuvantation of an H5N1 split-virion influenza
vaccine with AS03A substantially reduces the antigen dose
required to produce a putatively protective humoral
response and promotes cross-clade neutralizing responses.
We determined the effect of adjuvantation on antibody
persistence and B- and T-cell-mediated immune responses.
Methods Two vaccinations with a split-virion A/Vietnam/
1194/2004 (H5N1, clade 1) vaccine containing 3.75–30 μg
hemagglutinin and formulated with or without adjuvant
were administered to groups of 50 volunteers aged 18–
60 years.
Results Adjuvantation of the vaccine led to better persis-
tence of neutralizing and hemagglutination-inhibiting anti-
bodies and higher frequencies of antigen-specific memory
B cells. Cross-reactive and polyfunctional H5N1-specific
CD4 T cells were detected at baseline and were amplified
by vaccination. Expansion of CD4 T cells was enhanced by
adjuvantation.
Conclusion Formulation of the H5N1 vaccine with AS03A
enhances antibody persistence and induces stronger T- and
B-cell responses. The cross-clade T-cell immunity indicates
that the adjuvanted vaccine primes individuals to respond to
either infection and/or subsequent vaccination with strains
drifted from the primary vaccine strain.
Keywords CD4 T cells.pandemic influenza.AS03A.
H5N1.vaccine
Introduction
Novel influenza viruses arising as a result of antigenic shift
can potentially lead to an influenza pandemic in humans
due to the lack of immunity in the general population. The
2009 pandemic outbreak was due to the emergence of the
influenza A H1N1/2009 virus [1]. The highly pathogenic
avian influenza A H5N1 virus, which has been circulating
among poultry and birds in several countries during the last
decade, remains as a pandemic threat however due to its
potential to evolve into a strain with efficient human-to-
human transmission [2]. Concern about the H5N1 virus
focused attention on the development of pandemic vaccines
[3–6]. The experience gained using H5N1 as a model
antigen in vaccines can be applied to H1N1/2009 or other
pandemic strains. The principal strategy to develop H5N1
vaccines was based on the use of reverse genetics to
generate attenuated strains which express H5 surface
antigens [7, 8]. The formulation of H5N1 vaccines with
oil-in-water adjuvants has been found to substantially
enhance vaccine immunogenicity [9–15], thereby minimiz-
ing the amount of antigen required and alleviating pressure
on the limited global influenza antigen manufacturing
capacity.
We conducted a dose–response study with four antigen
doses (3.75, 7.5, 15, or 30 μg hemagglutinin antigen—HA)
of recombinant H5N1 (A/Vietnam/1194/2004 NIBRG-14,
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DOI 10.1007/s10875-010-9490-6clade 1) split-virion vaccine adjuvanted with AS03A, an oil-
in-water emulsion-based Adjuvant System containing α-
tocopherol, squalene, and polysorbate-80 [11]. The vaccine
was administered as a two-dose schedule to volunteers aged
18–60 years and the study included matched control groups
where the same antigen doses were administered without
adjuvant [11]. We demonstrated that adjuvantation with
AS03A conferred significant antigen sparing so that the
hemagglutination–inhibition (HI) antibody response with
the lowest antigen dose of 3.75 μg HA met all US and
European immunological licensure criteria [11]. Large
safety studies [16, 17] with the adjuvanted vaccine
indicated a clinically acceptable safety profile and the
vaccine has now been licensed in Europe [18].
Another important observation was the ability of AS03A-
adjuvanted H5N1 vaccine to induce cross-reactive seropro-
tective immune responses against heterologous recombinant
H5N1 strains. Thus, adjuvantation of the A/Vietnam/1194/
2004 H5N1 strain, which belongs to clade 1, induced cross-
reactive neutralizing responses against three other H5N1
strains associated with human disease belonging to clade 2
[11, 12]. The same vaccine was also shown to induce
protection against heterologous lethal H5N1 challenge in
ferrets [19]. An influenza vaccine with cross-immunogenic
potential could play a key role in pandemic mitigation by
promoting a rapid immune response to infection and/or
subsequent vaccination with strains drifted from the
primary vaccine strain.
Although an effective vaccination against influenza is
routinely measured in terms of the humoral response, it is
also important to monitor the induction of antigen-specific
T and B cells which are crucial components of the immune
response, particularly with respect to long-term memory. In
addition to the provision of CD4 T-cell help for B-cell
differentiation, both CD4 effector and memory T cells
appear to have multifaceted roles in the protective
responses to influenza infection [20, 21].
Here, we determine the effect of AS03A adjuvantation on
B- and T-cell responses following vaccination with the clade 1
H5N1 A/Vietnam/1194/2004 in the dose–response study. We
found that AS03A adjuvantation enhanced antibody persis-
tence, promoted stronger B-cell and CD4 T-cell responses and
induced polyfunctional cross-clade T-cell responses to two
heterologous clade 2 H5N1 isolates A/Indonesia/5/2005
(subclade 2.1) and A/Anhui/1/2005 (subclade 2.3).
Materials and Methods
Study Design and Participants
This was a single-centre, randomized, and observer-blind
phase I clinical trial to assess the safety and immunoge-
nicity of the candidate H5N1 vaccine. The Ethics
Committee of the Ghent University Hospital, Ghent,
Belgium, approved the protocol and other relevant study
documentation and the trial was registered with the
ClinicalTrials.gov registry (number NCT00309634). The
study was conducted according to the Declaration of
Helsinki, with written informed consent obtained from all
participants. Four hundred healthy male and female
volunteers aged 18 to 60 years were enrolled.
Procedures
A detailed account of the study procedures has been
published along with the results for the co-primary
objectives (safety and humoral immune responses at
day 42) [11, 12]. The inactivated split A/Vietnam/1194/
2004 (NIBRG-14) H5N1 vaccine was manufactured by
GlaxoSmithKline Biologicals. The vaccine strain, a recom-
binant H5N1 strain engineered by reverse genetics, was
obtained from the National Institute for Biological Stand-
ards and Control, UK. Two doses of the vaccine were
administered by deltoid muscle injection at 21 days apart to
eight groups of 50 volunteers (Fig. 1). Four HA antigen
doses (3.75, 7.5, 15, or 30 μg) were given with or without
AS03A, an oil-in-water emulsion-based Adjuvant System
containing α-tocopherol (11.86 mg) [11], (Morel et al.,
manuscript submitted).
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Fig. 1 Schematic representation
of the study design
444 J Clin Immunol (2011) 31:443–454Blood samples were collected at days 0, 21, 42, and 180
(Fig. 1). Peripheral blood mononuclear cells (PBMC) were
isolated by Ficoll-Hypaque (Lymphoprep, Life Technolo-
gies, Carlsbad, CA, USA) density centrifugation following
standard procedures. The cells were washed twice in
Hank’s balanced salt solution and cryopreserved in liquid
nitrogen until use.
Assessment of Antibody Response
Neutralization and HI assays were performed as described
previously [11].
Assessment of Memory B-Cell Response
Memory B cells were induced to differentiate into plasma
cells in vitro following cultivation of PBMC with
unmethylated DNA (CpG2006 at 3 μg/ml, Eurogentec,
Belgium) for 5 days [22]. In vitro-generated antigen-
specific plasma cells were enumerated using the memory
B-cell detection ELISPOT assay as described by Crotty et
al. [22]. Briefly, in vitro-generated plasma cells were
incubated in culture plates previously coated with 100 μl
of A/Vietnam/1194/2004 NIBRG-14 split antigen at
10 μg/ml or with 100 μl of anti-human IgG at 50 μg/ml
(Goat anti-human Affinipure, Jackson Laboratories) in
order to enumerate influenza-specific antibody or IgG
secreting plasma cells, respectively. The antibody/antigen
spots formed were detected by a conventional immuno-
enzymatic procedure. The results were expressed as
frequencies of influenza-specific memory B cells per
million of IgG-producing memory B cells.
Assessment of T-Cell Response
We used an adaptation of the method described by Maecker
and coworkers [23, 24] in which the T cells are
re-stimulated ex vivo by incubation with antigen in the
presence of costimulatory antibodies to CD28 and CD49d
[25] and Brefeldin A to inhibit cytokine secretion and allow
intracellular accumulation. The cells were then stained
using fluorochrome-conjugated antibodies to phenotypic
(CD4 or CD8) surface markers, intracellular cytokines, and
other markers before enumeration by flow cytometry. To
specifically measure the response to H5 antigen, cells were
stimulated ex vivo with influenza H5N1 split antigen or H5
peptide pools (with overlaps to ensure all that T-cell
epitopes are represented—see below) (Fig. 2). Recombinant
H5N1 strains derived from the clade 2 isolates A/Indonesia/
5/2005 and A/Anhui/1/2005 were provided by the Centers
for Disease Control and Prevention, Atlanta, GA, USA.
Peptides
Peptides (15-mer overlapping by 11 amino acids) spanning
the entire H5 HA antigen were synthesized by Eurogentech,
Belgium and shown to have >80% purity by HPLC.
Lyophilized peptides were reconstituted in phosphate-
buffered saline PBS/DMSO (less than 0.1% final concen-
tration). Six different pools of peptides were used for T-cell
stimulation. Three of these covered the H5 HA sequences
from (1) H5N1 A/Vietnam/1194/2004 (clade 1), (2) H5N1
A/Indonesia/5/2005 (subclade 2.1), and (3) H5N1 A/Anhui/
1/2005 (subclade 2.3). Three additional peptide pools,
comprising the sequences conserved between A/Vietnam
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Fig. 2 Overlapping peptides for
T cell stimulation. Sequences of
the A/Vietnam and A/Indonesia
HA proteins are shown with
overlapping peptides indicated
in black (conserved) or red
(non-conserved). Note that the
last conserved A/Indonesia
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J Clin Immunol (2011) 31:443–454 445and A/Indonesia or between A/Vietnam, A/Indonesia, and
A/Anhui or covering the A/Vietnam sequences that are not
conserved in A/Indonesia (Fig. 2), were used.
Antibodies
The antibodies used for cell stimulation were unconjugated
and azide-free anti-CD28 and anti-CD49d. The conjugated
antibodies used for staining were anti-CD3-PE-Cy5, anti-
CD4-PerCP,or-PacificBlue(PB),anti-CD8-allophycocyanin
(APC)-Cy7,anti-IFN-γ-FITCor-PE-Cy7,anti-IL-2-APCor-
FITC, anti-TNF-α-PE-Cy7, anti-CD40L-PE, anti-CCR7-
FITC, anti-CD45RA-PE, anti-CD27-AlexaFluor 700, and
anti-IL-13-PE (all BD Pharmingen, San Diego, CA, USA).
Cell Stimulation and Staining
Purified PBMC were thawed, washed twice in culture
medium (RPMI 1640, Cambrex, East Rutherford, NJ, USA)
supplemented with 10% heat-inactivated fetal calf serum
(FCS) (PAA Laboratories GMbH, Austria), 100 IU/ml
penicillin, 100 μg/ml streptomycin sulfate, 2 mM L-gluta-
mine, MEM nonessential amino acids, 100 mM sodium
pyruvate, 50 mM 2-mercapto-ethanol (all from Life Tech-
nologies, Belgium), examined for viability and counted
(Trucount, BD Biosciences, San Jose, CA USA), washed
again, and resuspended to 2×10
7 cells/ml in culture medium.
The PBMC (10
6 cells per well) were incubated in 96-well
microtiter plates with costimulatory anti-human CD28 and
CD49d antibodies (1/250 dilution each) and stimulated for
20 h at 37°C with either H5N1 split antigen from the A/
Vietnam/1194/2004 NIBRG-14 vaccine strain (final concen-
tration 1 μg/ml HA) or one of the peptide pools (final
concentration 1.25 μg/ml of each peptide). Brefeldin A (BD
Pharmingen, final concentration 1 μg/ml) was added for the
last 18 h of culture. Positive (Staphylococcus enterotoxin B,
1 μg/ml; Sigma-Aldrich, St. Louis, MO, USA) and negative
controls (unstimulated; no antigen) were included in each
assay. Following incubation, the cells were washed (PBS
containing 1% FCS) and stained with anti-CD4-PerCP and
anti-CD8- APC- Cy7. The cells were then washed again,
fixed, and permeabilized with the Cytofix/Cytoperm kit (BD
Pharmingen) according to instructions and stained with anti-
IFN-γ-FITC, anti-IL-2-APC, anti-TNF-α-PE Cy7, and anti-
CD40L-PE. Following washing (Perm/Wash buffer, BD
Pharmingen), the cells were analyzed by flow cytometry.
To characterize IFN-γ and IL-13 (Th1/Th2)-expressing T
cells after in vitro stimulation, we followed the same
protocol as described above but used anti-IFN-γ-PE-Cy7,
anti-IL-2-FITC, and anti-IL-13-PE for intracellular staining.
The procedure to characterize the memory phenotype of
antigen-specific T cells differed from the one described
above in that anti-CCR-7-FITC was incubated at the onset of
in vitro incubation, followed by extra-cellular staining with
anti-CD3-PE-Cy5.5, anti-CD4-PB, anti-CD8-APC-Cy7, and
anti-CD27-Alexa Fluor 700 in addition to anti-IL-2 APC and
anti-IFN-γ-PE Cy7.
Flow Cytometry
Cells were acquired on a FACSCanto flow cytometer
(Becton Dickinson) using six-color panels. Data were
analyzed using FACSDiva software. The results were
expressed as frequencies of CD4 or CD8 T cells responding
to the antigen and expressing two or more immune markers
among CD40L, IFN-γ, IL-2, and TNF-α per million total
CD4 or CD8 T cells. Background (unstimulated control)
was subtracted from all values. The remaining positive
events were regarded as significant. Samples were only
included for analysis if viability was 80% or more. The
analyses identifying the Th profiles and the memory
phenotypes of the specific T cells are described in the
“Results” section.
Data Analysis
The HI antibody response was presented in terms of
geometric mean titers (GMTs) at all time points for all
eight vaccine groups as well as in terms of seroconversion
rates (SCRs), i.e., the percentage of subjects with post-
vaccination titers ≥1:40 (deemed to be the seroprotective
threshold for seasonal influenza vaccines). We analyzed the
cellular immune responses (for 3.75 and 7.5 μgH A
formulations or 3.75 μg HA formulations only) for the
per-protocol population as the median (and interquartile
ranges Q1 and Q3) specific T or memory B cell numbers
per million total T or memory B cells prior to vaccination
(day 0) at 21 days following the first vaccine dose (day 21;
note that this time point was used only to measure T-cell
responses after stimulation with A/Vietnam/1194/2004
H5N1 split antigen), at 21 days following the second
vaccine dose (day 42), and at 180 days following the first
vaccine dose (day 180). The B-cell response endpoint was
the frequency of memory B cells responding to H5N1 split
antigen for each vaccine group. The T-cell response
endpoints were the frequencies of CD4 or CD8 T cells
expressing two or more immune markers among CD40L,
IL-2, TNF-α,a n dI F N - γ upon short term in vitro
stimulation with A/Vietnam/1194/2004 H5N1 split antigen
or H5 peptide pools. CMI results were further analyzed in
terms of CD4 Tcells expressing (1) CD40L and at least one
other marker (IFN-γ, IL-2, or TNF-α), (2) IL-2 and at least
one other marker (CD40L, TNF-α,o rI F N - γ), (3) TNF-α
and at least one other marker (CD40L, IL-2, or IFN-γ), or
(4) IFN-γ and at least one other marker (IL-2, TNF-α,o r
CD40L) for each vaccine group. To test the adjuvantation
446 J Clin Immunol (2011) 31:443–454and dose effects, we compared the B- or T-cell frequencies
in the adjuvanted and non-adjuvanted groups using the
Kruskal–Wallis test. Comparisons were done for day 42
values, for day 42 minus day 0 values (to account for any
differences in pre-vaccination day 0 values), and for
day 180 values.
Results
Antibody and B-Cell Responses
To evaluate the immunogenicity and safety of the
AS03A-adjuvanted A/Vietnam/1194/2004 H5N1 vaccine,
we conducted a single-center, randomized, observer-blind
phase I clinical trial [11]. The subjects in this trial received
two immunizations at a 21-day interval with either
adjuvanted or non-adjuvanted vaccine (Fig. 1). Blood
samples were collected at days 0, 21, 42, and 180 and used
for the analysis of antibody, B-cell, and CD4 T-cell
responses.
An analysis of neutralizing GMTs specific for A/
Vietnam/1194/2004 antigen provided a clear evidence for
the enhancing effect of adjuvant on both the magnitude [11]
and the persistence of the antibody response. Indeed the
enhancing effect of the adjuvant on the antibody response
against Vietnam/1194/2004 H5N1 was still evident at
6 months after the first vaccination (day 180) (Fig. 3a).
An evaluation of the SCRs of neutralizing and HI anti-
bodies supported this conclusion. Neutralizing antibody
SCRs at day 180 were 72% and 66% in the 3.75 and 7.5 μg
HA-adjuvanted groups versus 8% and 21% in the
corresponding non-adjuvanted groups, respectively (data
not shown). HI SCRs at day 180 were 54% and 64%
compared with 4% and 14% in the corresponding non-
adjuvanted groups for the 3.75 and 7.5 μg HA formula-
tions, respectively (Fig. 3b).
To determine whether the impact of the adjuvant on the
magnitude and persistence of the antibody responses would
be paralleled by enhanced B-cell responses, we measured the
frequencies of memory B cells specific for A/Vietnam H5N1
split antigen (further referred to as ‘split antigen’)a tt h e
differenttimepointsinthegroupsvaccinatedwiththe3.75μg
HA dose with or without adjuvant. H5N1-specific memory B
cells were detectable prior to vaccination (Fig. 4)a t
comparable frequencies in the two groups. At day 21
following the administration of the first vaccine dose,
increases in memory B-cell frequencies were observed in
both groups but the relative increase was higher in the
adjuvanted 3.75 μg HA group than in the non-adjuvanted
3.75 μg HA group (Fig. 4). The administration of the second
vaccine dose at day 21 further increased the response in the
adjuvanted group, as measured on day 42, but had no impact
in the non-adjuvanted group. Thus, the frequency of H5N1-
specific memory B cells was significantly higher in the
adjuvanted group versus the non-adjuvanted group when
assessed either as day 42 values (p< 0 . 0 0 1 )o ra sd a y4 2
minus day 0 values (p<0.001). The enhancing effect of the
adjuvant on the memory B-cell response observed on day 42
was still evident at day 180 (p<0.001) (Fig. 4). Similar
results were found for the higher 7.5 μg HA vaccine dose,
although in this case the data were only available for days 0
and 42 (Fig. 4).
CD4 T-Cell Response to A/Vietnam/1194/2004 H5N1 Split
Antigen
Following the observation that the adjuvant had a
positive effect on long-lived HI antibody responses and
memory B-cell frequencies, we investigated whether
these improved responses would be associated with
similar changes in the H5N1-specific CD4 T-cell
responses. To this end, A/Vietnam/1194/2004 H5N1-
specific CD4 T-cell responses were measured in the two
lowest dose groups (3.75 and 7.5 μg HA) with or
without adjuvant by intracellular cytokine staining
(Fig. 5a)[ 23, 24] following overnight stimulation of
PBMC with A/Vietnam/1194/2004 H5N1 split antigen and
using the expression of CD40L, IL-2, IFN-γ,a n dT N F - α
as read-outs. H5N1-specific CD4 T-cell responses, defined
as CD4 T cells producing at least two of these immune
markers after the stimulation, were evident in all the
groups prior to vaccination (Fig. 5a). Vaccination induced
increased frequencies of H5N1-specific CD4 T cells in all
groups (compare day 21 with day 0; Fig. 5a). However,
while a modest increase was observed in groups receiving
non-adjuvanted vaccine (p<0.0001 when comparing
d a y2 1o r4 2r e s p o n s et od a y0r e s p o n s e ) ,m u c hs t r o n g e r
responses were observed in the groups that received
adjuvanted vaccine. The second vaccination did not result
in an increase of the CD4 T-cell frequency when measured
at day 42, i.e., at 21 days after the second vaccination. The
adjuvant had a clear enhancing effect on the T-cell
response as demonstrated by the significantly higher
post-vaccination frequencies of H5N1-specific CD4 T
cells (when comparing adjuvanted and non-adjuvanted
formulations, p<0.0001 for day 21 and p<0.0001 for
d a y4 2v a l u e s )( F i g .5a). H5N1-specific CD4 T cells were
s t i l ld e t e c t a b l ea td a y1 8 0( F i g .5a), indicating the
persistence of the T-cell response. The frequencies
remained significantly higher (p=0.0001) in the adju-
vanted formulation groups as compared to the non-
adjuvanted ones at day 180. Both within the adjuvanted
and non-adjuvanted groups, no statistically significant
antigen dose effects on the H5N1-specific CD4 T-cell
response were observed (3.75 versus 7.5 μg HA) (Fig. 5a).
J Clin Immunol (2011) 31:443–454 447In six out of 200 subjects, antigen-specific CD8 T cells
producing IFN-γ and TNF-α were detected in pre-
vaccination samples following stimulation with split anti-
gen. However, vaccination did not have any impact on the
frequencies of these CD8 T cells as measured at 21 days
after vaccination (data not shown).
The H5N1-Specific CD4 T-Cell Pool is Composed
of Polyfunctional Effector and Memory Cells
The polyfunctionality of H5N1-specific CD4 T-cell responses
was evaluated on the basis of the expression patterns of
CD40L, IL-2, IFN-γ, and TNF-α in antigen-stimulated CD4
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Fig. 3 a Neutralizing antibody GMTs against the homologous A/
Vietnam/1194/2004 NIBRG-14 vaccine strain after the first and
second vaccine dose with 95% confidence intervals. Data shown for
all groups at the different time points. b SCRs of HI antibodies to the
homologous A/Vietnam/1194/2004 NIBRG-14 vaccine strain after the
first and second vaccine dose with 95% confidence intervals
448 J Clin Immunol (2011) 31:443–454Tcells. The predominant vaccine-induced response following
ex vivo stimulation with A/Vietnam/1194/2004 split antigen
consisted of CD40L- and IL-2-producing CD4 T cells
(Fig. 5b). A similar pattern was observed in H5N1-specific
CD4 Tcells at baseline (data not shown). When expressed as
antigen-specific CD4 T cells expressing at least two immune
markers (‘all doubles’), fewer CD4 T cells expressed IFN-γ
and/or TNF-α as compared to CD40L/IL-2-double-positive
CD4 Tcells (Fig. 5b). This pattern was observed for both the
3.75 and 7.5 μg HA formulations (Fig. 5b). In each
subpopulation, higher frequencies were observed in the
adjuvanted groups (Fig. 5b). Indeed the frequencies of all
polyfunctional H5N1-specific CD4 T cells (expressing all
marker combinations) at day 42 were significantly higher in
the adjuvanted 3.75 and 7.5 μg HA formulation groups than
in the corresponding non-adjuvanted formulation groups (all
p<0.0001 for both day 42 values and day 42 minus day 0
values) (data not shown).
To examine the Th1/Th2 balance of the response, IL-13
production in antigen-specific CD4 T cells was analyzed by
intracellular cytokine staining and compared with IFN-γ
expression in adjuvanted and non-adjuvanted groups
(Fig. 6). PMA/ionomycin-stimulated CD4 T cells were
used as a positive control for IL-13 staining (data not
shown). Very few IL-13-producing CD4 T cells were
detected at day 42, whereas IFN-γ/IL-2 double-positive
CD4 T cells were readily observed. In addition, no increase
in the frequencies of IL-13-secreting CD4 T cells was
observed when comparing day 42 with day 0 (Fig. 6).
Having established that H5N1 vaccination leads to an
increase in the frequencies of polyfunctional H5N1-specific
CD4 T cells, we next evaluated the phenotypic character-
istics of these cells and their differentiation into memory
cells. To this end, CD45RA, CCR7, and CD27 were used
as phenotypic markers to distinguish effector, effector–
memory, and central memory T cells [20, 26–28]. H5N1-
specific CD4 T cells were identified as IFN-γ- and/or IL-2-
producing CD4 T cells after stimulation with either H5N1
split antigen or a pool of overlapping peptides spanning the
entire A/Vietnam/1194/2004 H5 HA sequence (Fig. 2). All
H5N1-specific CD4 T cells, at day 42, were CD45RA
neg
(data not shown). Cytokine expression patterns clearly
revealed three different populations of antigen-specific CD4
T cells: IL-2
+/IFN-γ
−, IL-2
−/IFN-γ
+, and IL-2
+/IFN-γ
+
(Fig. 7a). A phenotypic analysis of these three populations,
using CCR7 and CD27 as markers, revealed that the IL-2
−/
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+ cells were mainly CCR7
− CD27
− effector/effector–
memory cells, whereas the population of IL-2
+ T cells, with
or without IFN-γ, respectively (IL-2
+/IFN-γ
+ and IL-2
+/
IFN-γ
−), consisted of CCR7
+ CD27
+ central memory cells
and CCR7
− CD27
+ effector–memory cells (Fig. 7a). A
quantitative analysis indicated that the response was
dominated by CCR7
− CD27
+ effector–memory CD4 T
cells, with smaller populations of CCR7
+ CD27
+ central
memory cells and CCR7
− CD27
− effector/effector–memory
cells (Fig. 7b). Although the amplitude of the H5N1-
specific response was significantly higher in the groups
vaccinated with adjuvanted vaccine, the ratios between the
three major populations were stable over time (day 42
compared to day 180), were similar to the pre-vaccination
pattern, and did not differ between the adjuvanted and non-
adjuvanted groups (Fig. 7b).
H5N1 A/Vietnam/1194/2004 vaccine-induced CD4 T-cell
responses are clade 2 cross-reactive
As we have shown previously, vaccination with the clade 1
H5N1 A/Vietnam/1194/2004 vaccine induced clade 2
cross-reactive neutralizing antibodies [11, 12]. To deter-
mine whether this cross-reactive humoral response was
associated with similarly cross-reactive CD4 T-cell
responses, PBMC were stimulated with sets of peptides
spanning the HA sequences from A/Vietnam/1194/2004
(clade 1) and the clade 2 strains H5N1 A/Indonesia/5/2005
(subclade 2.1) and A/Anhui/1/2005 (subclade 2.3) (Figs. 2
and 8a). With respect to the A/Vietnam-specific responses,
it was observed that the absolute frequencies of CD4 Tcells
responding to the peptide pool (Fig. 8b) were lower than
those observed after H5N1 split antigen stimulation
(Fig. 5a). A possible explanation for this difference may
be that the peptide pools do not contain split virus
components such as the neuraminidase N1 protein. Never-
theless, HA-specific CD4 T-cell responses were observed
for all six peptide pools used, at day 42 as well as at day 0,
albeit to a lower extent (Fig. 8b). These data demonstrate
that the clade 1 H5N1 A/Vietnam/1194/2004 vaccine
induced a clade 2 cross-reactive CD4 T-cell response (A/
Indonesia/5/2005 and A/Anhui/1/2005) and also confirm
that a pool of cross-reactive CD4 T cells existed before
vaccination. In all cases, responses were dominated by
CD40L
+ IL-2-producing CD4 T cells, with fewer cells
expressing IFN-γ and TNF-α (data not shown). Thus, the
CD40L and cytokine expression patterns of the HA-specific
CD4 T cells for all three H5N1 strains were similar to those
observed after the stimulation with the A/Vietnam/1194/
2004 split antigen (Fig. 5b). In addition, the responses were
measured against the conserved regions of the HA antigen
using two peptide pools covering the sequences that are
identical between A/Vietnam and A/Indonesia or between
all three H5N1 strains. Finally, the responses were
measured against the region that is unique to the A/Vietnam
strain (Figs. 2 and 8a). As might be expected, a response
was evident following ex vivo stimulation with the peptide
pool covering the conserved region (Fig. 8b). Also, a CD4
T-cell response was observed to the peptide pool spanning
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450 J Clin Immunol (2011) 31:443–454the region that is unique to A/Vietnam/1194/2004 (Fig. 8b).
In all cases, cross-reactive CD4 T-cell responses were
clearly enhanced by the presence of the adjuvant.
Discussion
Wehavepreviouslyshownthattheformulationofaclade1A/
Vietnam/1194/2004 H5N1 split-virion vaccine with an α-
tocopherol containing oil-in-water emulsion-based Adjuvant
System (AS03A) induced broad clade 2 cross-reactive
humoral immunity and reduced the amount of antigen
required to produce a humoral response that meets the
European Union Committee for Medicinal Products for
Human Use and US Food and Drug Administration licensure
criteria [11, 12]. Two doses of adjuvanted H5N1 split-virion
vaccine containing 3.75 μg HA induced high levels of
neutralizing and HI antibodies against the clade 1 vaccine
strain, as well as a significant cross-reactive neutralizing
antibody response against the clade 2 H5N1 isolates A/
Indonesia/5/2005 (subclade 2.1), A/turkey/Turkey/1/2005
(subclade 2.2), and A/Anhui/1/2005 (subclade 2.3) [11,
12]. Here, we have investigated the CD4 T-cell and memory
B-cell responses underlying these cross-reactive antibody
responses. CD4 T-cell responses were detected by intracel-
lular cytokine staining after stimulation with either split virus
or overlapping peptides. The present study makes four
points: First, we show that all responses, i.e., antibodies, B
cell memory, and CD4 T cells, are increased when the
vaccine is formulated with AS03A adjuvant. Second,
persistent neutralizing antibody responses are mirrored by
long-lived memory B-cell responses. Third, vaccination
induces polyfunctional and highly cross-reactive CD4 T-
cell responses and results in long-lived central and effector
CD4 T-cell memory. Fourth, H5N1-specific CD4 T and
memory B cells are already detected before vaccination.
We observed stronger memory B-cell responses for the
H5N1 antigen when the vaccine was formulated with
adjuvant. Memory B-cell frequencies were increased after
the first vaccination and rose further after the second
vaccination. Since antibody-secreting plasma cells and mem-
ory B cells may represent independently regulated cell
populations [29], long-lived memory B cells may not play
a direct role in the maintenance of antibody levels, but they
could differentiate into plasma cells after booster vaccination
or natural infection. Therefore, higher levels of memory B
cells would predict a better ‘boostability’ of the response. We
further observed increased H5N1-specific CD4 T-cell
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J Clin Immunol (2011) 31:443–454 451responses with the adjuvanted vaccine. The frequencies of
antigen-specific, polyfunctional CD4 T cells increased
strongly at day 21 post-vaccination with the adjuvanted
vaccine. There appeared to be no increase in the response
after the second vaccination, i.e., at day 42. A possible
explanation for this perceived lack of further expansion is
that the peak of the CD4 T-cell response occurred earlier
after the second vaccination [30] and that the day 42 time
point measures the response in the contraction phase.
Alternatively, it is possible that specific CD4 T cells may
have migrated towards the injection site, thereby affecting
CD4 T-cell frequencies in peripheral blood. The fact that the
response levels at days 21 and 42 were nearly identical may
suggest that the antigen-specific CD4 T cells underwent an
expansion phase prior to the day 42 sampling time point.
Further investigation of the kinetics of the response should
shed further light on this question.
Phenotypically, the responding CD4 T-cell population
consisted of both effector–memory-like cells (CD45RA
−,
CCR7
−,C D 2 7
+/−) and central memory cells (CD45RA
−,
CCR7
+,C D 2 7
+) with a tendency for CCR7
− CD27
+ effector–
memory cells to dominate the response at day 180. Overall,
the adjuvanted vaccine induced a significantly larger memory
pool as compared to the non-adjuvanted vaccine. The
functional profiles of the responding CD4 T cells were similar
for both adjuvanted and non-adjuvanted vaccines, with
responses being dominated by CD40L
+- and IL-2-producing
cells. Fewer IFN-γ-a n dT N F - α-producing cells were evident.
This bias towards IL-2-producing CD4 T cells was noted
previously in healthy adults that received the hepatitis B virus,
tetanus, or diphtheria vaccines [30, 31] and it has been
suggested that this phenotype is typical for protein subunit
vaccines in general [31].
Overall, the H5N1-specific CD4 T-cell responses had a
Th1 bias and very few IL-13-producing cells were detected at
any time point. Confirming recently published results [32],
cross-reactive CD8 T-cell responses were measured at
baseline, indicating the capacity of our assay to detect CD8
T-cell responses. However, no increased CD8 T-cell
responses were observed after vaccination, which is in
contrast to the responses usually induced by a viral infection
[33]. Indeed FluMist® (MedImmune LLC, Gaithersburg,
MD), which is a live-attenuated influenza vaccine, induces
CD8 T-cell responses [20]. Besides the antigen content, the
most likely explanation for this is that protein antigens are
efficiently presented through the MHC class II pathway but
not via the MHC class I pathway. The induction of CD8 T-
cell responses to protein antigen depends on the cross-
presentation pathway which, in mice, critically depends on
type-I IFN [34] and specialized CD8α
+ DCs, but which is
not yet fully understood in humans.
Immune responses to inactivated influenza virus adju-
vanted with a different oil-in-water emulsion, MF59, have
recently been described [35, 36]. Although a direct
comparison between the adjuvants is complicated by the
fact that different methodologies may have been used to
measure immune responses, our data indicate that AS03A-
adjuvanted influenza vaccines induce strong HI responses
and CD4 T-cell frequencies relative to those induced with
the MF59-adjuvanted product.
It is interesting to note that H5-specific CD4 T cells and
H5N1-specific memory B cells were detectable prior to
vaccination. The identification of CD4 T-cell responses
after peptide stimulation in day 0 samples clearly indicates
that an H5-specific T-cell response exists before vaccina-
tion. However, since the split antigen used for the
stimulation of B cells and CD4 T cells also contains the
neuraminidase (NA) protein, it cannot be excluded that part
of the pre-existing response was in fact specific for NA.
Indeed there was a discrepancy between readily detected
pre-existing H5N1-specific memory B cells and weaker
pre-existing A/Vietnam-specific HI responses (detectable in
only seven of 400 subjects (11)).
No correlations were observed between the frequencies
of pre-existing H5N1-specific CD4 T cells and post-
vaccination HI titers at days 42 or 180. Moreover, there
was no correlation between the frequencies of pre-existing
H5N1-specific CD4 T cells and post-vaccination CD4 T-
cell responses, suggesting that at least part of the response
is not dependent on pre-existing CD4 memory T cells.
Pre-existing memory CD4 T cells responded to peptide
pools covering the HA sequences from the clade 1 A/
Vietnam/1194/2004 vaccine virus as well as the clade 2 A/
Indonesia virus. This suggests that the H5-cross-reactive CD4
T cells were induced by a previous infection with seasonal
influenza. Thus, these results confirm recently published data
showing that memory CD4 T cells, and also CD8 T cells,
established by seasonal influenza A cross-react with H5N1
strains [32]. The combined data raise the question on
whether this memory T-cell pool expands after vaccination,
instead of or in addition to the naïve T-cell repertoire. A
further question is how this potential balance between the
recruitment of naïve and memory responses is affected by
the adjuvant. A related question is whether the adjuvant
simply amplifies the response induced by the non-
adjuvanted vaccine (i.e., more of the same) or whether it
induces qualitative changes in the repertoire of the respond-
ing T cells (i.e., more but not the same). Recent data indicate
that vaccine adjuvants change the clonal composition of
antigen-specific CD4 T-cell populations responding to
vaccines, favoring the selection of higher-affinity T cells
[37]. Thus, it seems likely that the adjuvant changes the T-
cell response both quantitatively and qualitatively.
Adjuvantation of the split antigen vaccine with AS03A
resulted in a strong increase in the numbers of antigen-
specific B cells and CD4 T cells. AS03A does not contain a
452 J Clin Immunol (2011) 31:443–454‘classical’ TLR ligand and further studies into its mode of
action are ongoing. Based on the results presented here and
our recent data on the mode of action of the AS03A
Adjuvant System (Morel et al., manuscript submitted), we
propose the following model: AS03A induces a recruitment
of neutrophils and monocytes at the injection site and
induces the maturation of the recruited monocytes. Indeed
AS03A activates monocytes and macrophages but not
dendritic cells (Morel et al., manuscript submitted). Our
current data show that the presence of α-tocopherol in
AS03 was required to achieve an optimal antibody response
in mice immunized with HBsAg (Morel et al., manuscript
submitted). Furthermore, the presence of α-tocopherol in
the AS03A Adjuvant System modulated the levels and
kinetics of other cytokines and chemokines, including
CCL2, CCL3, IL-6, CSF3, and CXCL1, increased the
antigen loading in monocytes, and increased the recruit-
ment of granulocytes in the draining lymph nodes (Morel et
al., manuscript submitted). Thus, the ability of α-tocopherol
to qualitatively and quantitatively modulate the innate
immune response is correlated with a positive impact on
the adaptive immune responses in pre-clinical models.
Interestingly, IL-6 has been involved in the induction of
follicular T helper cells [38] which are essential to provide
B-cell help and to promote germinal center reactions. This,
in turn, could lead to increased antibody responses.
Conclusions
Insummary,weshowthattheAS03A-adjuvanted H5N1 split-
virion vaccine is capable of inducing superior antibody,
memory B-cell and CD4 T-cell responses when compared to
non-adjuvanted vaccine and that the CD4 T-cell responses
were notably cross-reactive with clade 2 viruses. The
induction of cross-clade immune responses clearly indicates
that H5N1 vaccines formulated with AS03A could prime
against infection or revaccination with drifted strains. This
property of the adjuvanted vaccine is appealing in the
context of the development of a vaccine against the 2009
H1N1 A/California pandemic strain and the potential of this
vaccine to protect against drifted strains.
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